2008

Sub-Investigator - S0500: A Randomized Phase III Trial to Test the Strategy of  Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment

2008

Sub-Investigator – E5597  Randomized Phase III Chemopreventive Trial of
Selenium Supplements in Persons with Resected Stage I NSCLC.

2008

Sub-Investigator - S0421: Phase III Study of Docetaxel and Atrasentan versus    
Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer.

2008

Sub-Investigator - RTOG-0521:  A Phase III Protocol of Androgen Suppression
(AS) and 3DCTR/IMRT vs. AS and 3DCTR/IMRT followed by Chemotheraphy with Docetaxel and Prednisone for Localized, High-Risk, Prostate Cancer.

2008

Sub-Investigator - RTOG-0232:  A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachyteraphy with Brachyteraphy alone for Selected Patients with Intermediate Risk Prostatic Carcinoma.

2008

Sub-Investigator – N0574: A Phase III Randomized Trial of the Role of Whole Brain Radiation Theraphy in Addition to Radiosurgery in Patients with One to Three Cerebral Metastases.

2008

Principal Investigator - Novartis Pharmaceuticals Corp:
A prospective, Randomized, Multi-Center, 3 arm of the continued efficacy and        safety of Zometa in patients with documented bone metastases from Breast cancer.  Protocol # CZOL446E2352.

2008

Sub-Investigator –AMGEN Pharmaceuticals: Amgen Protocol# 20050154:  Phase 2,
Randomized, Double Blind, Placebo-Controlled Dose and Schedule Finding Trial to   Evaluate the Safety and Efficacy of AMG 531 For Treatment of  Chemotherapy-Induced Trombocytopenia In Subjects with Advance Non-Small Cell Lung Cancer Already Receving Gemcitabine and Platinum.   

2008

Sub-Investigator – GPC Biotech Inc.: Protocol # SAT3-06-04 Expanded Access Study of Satraplatin Plus Prednisone in Patients with Hormone Refratory Prostate Cancer Previously Treated with Unlimited Cytotoxic Chemotherapy Regimens

2008

Sub-Investigator - Millennium Pharma., : Protocol # C05009: Phase IIIB, randomized study of three treatment regimens in subjects with previously untreated Multpile Myeloma who are not considered candidates High Dose Chemotherapy and Autologous Stem Cell Transplatation.  Velcade, Thalomide & Dexamethasone (VTD) vs. Velcade and Dexamethasone (VD) Vs. Velcade, Melphalan, and Prednisone (VMP).

2008

Sub-Investigator  - NSABP-B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer.

2008

Principal-Investigator - E5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer.

2008

Sub-Investigator - IBCSG-2402:  Phase III Randomized Study of Ovarian Function Suppression in Combination With Tamoxifen Versus Ovarian Function Suppression in Combination With Exemestane Versus Tamoxifen Alone in Premenopausal Women With Endocrine-Responsive Breast Cancer.

2008

Sub-Investigator -  NSABP-B-39: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer

2007

Principal Investigator - Novartis Pharmaceuticals Corp:
A prospective, Randomized, Multi-Center, 3 arm of the continued efficacy and     safety of Zometa in patients with documented bone metastases from Breast cancer.  Protocol # CZOL446E2352.

2007

Sub-Investigator –AMGEN Pharmaceuticals: Amgen Protocol# 20050154:  Phase 2,
Randomized, Double Blind, Placebo-Controlled Dose and Schedule Finding Trial to   Evaluate the Safety and Efficacy of AMG 531 For Treatment of  Chemotherapy-Induced Trombocytopenia In Subjects with Advance Non-Small Cell Lung Cancer Already Receving Gemcitabine and Platinum.   

2007

Sub-Investigator – GPC Biotech Inc.: Protocol # SAT3-06-04  Expanded Access
Study of Satraplatin Plus Prednisone in Patients with Hormone Refratory Prostate
Cancer Previously Treated with Unlimited Cytotoxic Chemotherapy Regimens.

2007

Sub-Investigator for Millennium Pharma., : Protocol C05009: Phase IIIB, randomized study of three treatment regimens in subjects with previously untreated Multpile Myeloma who are not considered candidates High Dose Chemotherapy and Autologous Stem Cell Transplatation.  Velcade, Thalomide & Dexamethasone (VTD) vs. Velcade and Dexamethasone (VD) Vs. Velcade, Melphalan, and Prednisone (VMP).

2006

Principal Investigator – ECOG endorsed study:  NSABP B-38 - Phase III Randomized Study of Three Different Adjuvant Chemotherapy Regimens Comprising Docetaxel, Doxorubicin, and Cyclophosphamide Versus Dose-Dense Doxorubicin, Cyclophosphamide, and Paclitaxel Versus Dose-Dense Doxorubicin, Cyclophosphamide, Paclitaxel, and Gemcitabine in Women With Node-Positive Breast

2006

Sub-Investigator – ECOG endorsed study:  E1F03 - A Phase II Study of Temozolomide and Radiation Therapy in Patients with Brain Metastasis from Non-small Cell Lung Cancer.

2006

Sub-Investigator – ECOG endorsed study: S0424 - Molecular Epidemiology Case-Series of Non-small Cell Lung Cancer in Smoking and Non-Smoking Women and Men.

2006

Sub-Investigator – ECOG endorsed study:  CALGB-90401 - A Randomized Double-Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone with and without Bevacizumab (IND #7921, NSC #704865) In Men with Hormone Refractory Prostate Cancer.

2006

Sub-Investigator – Bayer Pharmaceuticals:  An Open Label, Non omparativeTreatment Protocol for the use of Sorafenib in Patients with Advanced Renal Cell Carcinoma.  Protocol #11868.

2005

Sub-investigator – F. Hoffmann – La Roche LTD/INC/AG:  Randomized, Two-Arm, Placebo Controlled Double Dummy Study to Compare the Efficacy of Intravenous Loading Doses Followed by Maintenance Treatment with Oral Ibandronic Acid versus Zoledronic Acid in Patients with Skeletal Metastases Experiencing Moderate to Severe Pain,  Protocol # Bo 18039A.

2005

Sub-investigator – Sanofi-Synthelabo, Inc.:  A Phase IV, Randomized, PROSPECTIVE, Multicenter Comparison of an Intermittent schedule of Oxaliplatin (IO) combined with 5-Fluorouracil/Leucovorin (FOLFOX) /  Bevacizumab versus the Conventional (CO) Mode of  Administration of FOLFOX/Bevacizumab +/- Neuroprophylaxis with Calcium/Magnesium for the Optimazation of First-Line Therapy of  Metastatic ColorectaL Cancer, Protocol #L_9444 – CONCEPT.

2004

Sub-investigator – GlaxoSmithKline:  A Phase 2, Multicenter Trial Comparing Two Schedules of GW570216 as First Line Monotherapy in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Protocol #EGF20014.

2004

Principal Investigator – GlaxoSmithKline:  A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III        Study of Oral GW572016 in Combination with Paclitaxel in Subjects Previously Untreated for Advanced or Metastatic Breast Cancer, Protocol #EGF30001

2004

Sub-investigator – Amgen, Inc.:  SYNCHRONICITY:  A Study to Evaluate the Effectiveness of Aranesp® at 300 mcg Q3W on Clinical Outcomes in Cancer Patients with Anemia Due to Chemotherapy, Protocol #Aranesp® 20030206

2004

Principal Investigator -  Pharmion Corporation: Treatment Use with Azacitidine, an Investigational Drug, in Myelodysplastic Syndromes, Protocol #AZA PH GL 2003 CL 002.

2004

Sub-investigator – Spectrum Pharmaceuticals:  A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPP 28090) in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma, Protocol # ELSA 2004-001

2004

Sub-investigator – Cell Genesys, Inc:  A Phase III Randomized, Open-Label Study of CG1940 and CG8711 versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naïve, Protocol #G-0029.

2004

Sib-investigator – Oncotherapeutics:  A Phase I/II Trial of Zometa in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS), Protocol #ZOMGUS-001

2004

Sub-investigator – Pharmatech Oncology:  A Randomized, Multicenter Study of Combination Gemcitabine Therapy Followed by Subsequent Single Agent Gemcitabine Maintenance Therapy or Best Supportive Care in Advanced Non-Small Cell Lung Cancer (NSCLC), Protocol #PO1-01-003-050

2004

Sub-investigator – Genentech, Inc. and Biogen Idec:  The National Lymphocare Study:  An Observational Study of Treatment, Outcomes, and Prognosis in Patients with Follicular Non-Hodgkin’s Lymphoma, Protocol #U2963n

2004

Sub-investigator – Genentech, Inc.:  A Multicenter, Open-Label, Phase IIIb Trial of Tarceva™ (Erlotinib Hydrochloride) in Patients with Advanced Non-Small Cell Lung Cancer, Protocol #OS13199g-A1.

2004

Principal Investigator – ECOG endorsed study:  IBCSG-2502 - Phase III Randomized Study of Triptorelin and Exemestane Versus Triptorelin and Tamoxifen in Premenopausal Women With Endocrine-Responsive Breast Cancer. 

2004

Sub-investigator – ECOG Study:  E1Y97: ECOG Laboratory Study:  Mapping Interactive Cancer Susceptibility Loci in Siblings with the same Cancer (Breast, Prostate, Lung or Colon)

2004

Sub- Investigator – ECOG endorsed Study:  S9917: L-Selenium-Based Chemoprevention of Prostate Cancer Among Men with High Grade Prostatic Intraepithelial Neoplasia.

2004

Sub-investigator – ECOG Study:  E5597: Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer

2004

Sub-investigator – ECOG-endorsed Study:  CALGB80101 – Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma.

2004

Sub-investigator – ECOG-endorsed Study:  RTOG0214 – Phase III Comparison of Prophylactic Cranial Irradiation Versus Observation in Patients with Locally Advanced Non-Small Cell Lung Cancer.

2003

Sub-investigator – Pro Neuron, Inc:  An Open-label, Randomized, Controlled, Phase III, Multicenter, Clinical Trial of PN401 with High Dose 5-Fluorouracil (5FU) versus Gemcitabine for Treatment pf Patients with Advanced Pancreatic Cancer, Protocol #401.00.001

2003

Sub-investigator – Novartis:  A Randomized, Double-bind, Placebo-Controlled, Phase III Study of Oxaliplatin/5-Fluorouracil/Leucovorin with PTK787/ZK 222584 or Placebo in Patients with Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum, Protocol #CPTK787-0133/304946

2003

Sub- Investigator – Novartis:  A Randomized, Double-Blind, Placebo-Controlled, Phase III Study in Patients with Metastatic Adenocarcinoma of the Colon or Rectum Who are Receiving First-Line Chemotherapy with Oxaliplatin/5-Fluorouracil/Leukovorin and PTK787/ZK 222584 or Placebo, Protocol #CPTK 787 0135/306241

2003

Sub-investigator (2003)/Principal Investigator (2004) – Solvay Pharmaceuticals:  A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Efficacy Study of Oraldronabinol Alone and in Combination with Ondansetron versus Ondansetron Alone in Subjects with Delayed Chemotherapy-Induced Nausea & Vomiting, Protocol #S1753102.

2003

Sub-investigator – Sanofi-Synthelabo, Inc.: A Randomized, Prospective Study Comparing Three Regimens of Eloxatin™ Plus Fluoropyrimidine and Avastin for Evaluation of Safety and Tolerability in First Line Treatment of Patients with Advanced Colorectal Cancer (Tree 2 Study), Protocol #ARD5099

2003

Sub-investigator – Bristol Myers Squibb:  A Phase II Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second-Line  Treatment in Patients with Metastatic, EGFR-Positive Colorectal Carcinoma, Protocol #CA225006

2003

Sub-investigator – Supergen, Inc.:  A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in the Treatment of Previously Untreated and Treated, Stage III or IV, Low-Grade B-Cell Non-Hodgkin’s Lymphoma, Protocol #PO1-02817.

2003

Sub-investigator – Supergen, Inc.:  A Multicenter, Open-Label Study of Nipent, Cytoxan, and Rituxan in Patients with Previously Untreated Chronic Lymphocytic Leukemia, Protocol #PO1-02818

2003

Sub-investigator -  Dendreon Corp.: A Randomized, Double-Blind, Placebo Controlled Phase 3 Trial of Immunotherapy with Autologous Antigen Presenting Cells Loaded with PA2024 (Provenge® APC8015) in Asymptomatic Subjects with Gleason Sum < 7, Metastatic, Androgen Independent Prostatic Adenocarcinomas, Protocol #Dendreon 9902B.

2003

Sub-investigator – Eli Lilly & Co.:   Open-Label Study of ALIMTA (pemetrexed) in Combination with Cisplatin for Chemonaive Patients with Malignant Pleural Mesothelioma, Protocol #H3E-US-JMFE.

2003

Principal investigator – Alza Corporation:  An Open-Label, Single-Arm, Phase II Study of Liposomal Doxorubicin (Doxil®) and Gemcitabine in the Treatment of Women with Metastatic Breast Cancer, Protocol #POI-00-002-008.

2003

Principal Investigator – Bristol Myers Squibb:  A Phase III Trial of Novel Epothilone BMS-247550 Plus Capecitabine versus Capecitabine Alone in Patients with Advanced Breast Cancer Previously Treated with or Resistant to an Anthracycline and Who are Taxane Resistant, Protocol #CA163-046-154

2002

Sub-investigator: SuperGen, Inc.: Phase III Randomized Study of RFS 2000 (9-Nitro-camptothecin, 9-NC) versus Gemcitabine HCl in Chemonaive Pancreatic Cancer Patients, Protocol #RFS2000-02.

2002

Sub-investigator:  SuperGen, Inc.:  Phase III Study of RFS 2000 (9-Nitro-camptothecin, 9-NC) Versus Most Appropriate Chemotherapy in Refractory Pancreatic Cancer Patients, Protocol #RFS2000-09.

2002

Sub-investigator – Dendreon Corp.: A Randomized Double Blind, Placebo-Controlled Trial of Immunotherapy with Autologous Antigen-Loaded Dendritic Cells (APC8015) for Asymptomatic Hormone-Refractory Prostate Cancer, Protocol #D9902

2002

Sub-investigator  - Dendreon Corp. :   A Phase II, Open Label, Single Arm Trial with Cryopreserved Autologous Antigen-Loaded Dendritic Cells (APC8015F) for Hormone-Refractory Prostate Cancer Patients with Objective Disease Progression, Protocol #D9903

2002

Sub-investigator – Breast Cancer International Research Group (BCIRG): A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination with Doxorubicin and Cyclophosphamide (TAC) versus Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC à T) as Adjuvant Treatment of Operable Breast Cancer HER2NEU Negative Patients with Positive Axillary Lymph Nodes, Protocol #BCIRG 005.

2002

Sub-investigator – Astra-Zeneca Pharmaceuticals: A Randomized, Double-Blind, Phase III Comparative Trial of 2 Doses of ZD 1839 (IRESSA) in Combination with Gemcitabine and Cisplatin Versus Placebo in Combination with Gemcitabine and Cisplatin in Chemotherapy-naïve Patients with Advanced (Stage III or IV) Non-Small Cell Lung Cancer, Protocol #1839IL/0014.

2002

Sub-investigator – Isis Pharmaceuticals, Inc.:  A Pilot Trial of ISIS 3521, an Antisense Inhibitor of Protein Kinase C Alpha, Combined with Gemcitabine and Cisplatin Chemotherapy in Patients with Advanced Cancer (Part 1) or Advanced Previously Untreated Non-Small Cell Lung Cancer (Part 2), Protocol #ISIS 3521-CS15.

2002

Sub-investigator – Aventis Pharmaceutical Products: A Pilot Feasibility Study to Evaluate Patient Recruitment, Safety, Efficacy, and Compliance for a 180 Day Period of Enoxaparin Alone versus Enoxaparin Followed by Warfarin in the Secondary Prevention of Venous Thromboembolism in Patients with Active Malignancy, Protocol #ENO.USA.402.

2002

Sub-investigator - Astra-Zeneca Pharmaceuticals: An Expanded Access Clinical Program with ZD1839 (IRESSA™) for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), Protocol #1839IL/0050.

2002

Sub-investigator – Sanofi-Synthelabo Research: A Multicenter Open-Label, Randomized, Three-Arm Study of 5-Fluouracil (5-FU) Plus Leucovorin (LV) or Oxaliplatin or a Combination of 5-FU/LV + Oxaliplatin as Second-Line Treatment of Metastatic Colorectal Carcinoma, Protocol EFC 4584

2002

Sub-investigator – Smith, Kline Beecham:  A Phase II Study of Topotecan and Paclitaxel as First-Line Treatment in Patients with Extensive Disease Small Cell Lung Cancer, Protocol #104864-A/435.

2002

Sub-investigator – Aventis Pharma and Breast Cancer International Research Group (BCIRG): A Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC à) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (ACàH) and with Docetaxel, Platinum Salt and Trastuzumab (TCH) in the Treatment of Node Positive and High Risk Node Negative Adjuvant Patients with Operable Breast Cancer Containing the HER2NEU Alternation, Protocol #BCIRG 006

2002

Sub-investigator – Alza Corporation:  A Multi-Center Randomized Study of Vincristine, Doxil® and Dexamethasone vs. Vincristine, Doxorubicin and Dexamethasone in Patients with Multiple Myeloma, Protocol #C-2000-003-01.

2002

Sub-investigator – Chiron Corporation:  Interleukin-2 in an Alternative Dose (The ILIAD Trial):  Treatment of Patients with Metastatic Renal Cell Carcinoma with Low-Dose Proleukin®, Protocol #ILIAD, (MA-99-01).

2002

Sub-investigator – Amgen, Inc.:  A Phase II Trial of Filgrastim-SD/01 to Support Carboplatin/Paclitaxel for the Treatment of Subjects with Stage IIIb/IV Non-Small Cell Lung Cancer, Protocol #PO1-01-001-006.

2002

Sub-investigator – Roche Laboratories: A Pilot Trial of Two Different Doses of Capecitabine (XELODA) in Patient with Advanced Metastatic Breast Cancer, Protocol #XEL-154.

2002

Sub-investigator – Los Angeles Hematology/Oncology Medical Group:   Protocol IND: 55, 291:  A Phase I//II Study of Arsenic Trioxide in Combination with Cytosine Arabinoside in Patients with Myelodysplastic Syndrome.

2002

Sub-investigator – Sarah Cannon Cancer Center/Minnie Pearl Cancer Center/OCOG:
A Phase II Trial of Arsenic Trioxide and Thalidomide in the Treatment of Patients with Refractory Multiple Myeloma, Protocol #MM03, OCG #2019.

2002

Sub-investigator – Genentech, Inc: Clinical Outcomes in Patients with HER2Gene-Amplified Metastatic Breast Cancer Treated with First-Line Herceptin® in Combination with a Taxane:  A Phase IV, Prospective, Community Based Study, Protocol #N225n.

2002

Sub-investigator – Dana-Farber Institute: Trastuzumab (Herceptin) and Either Vinorelbine (Navelbine) or Taxane-Based Chemotherapy in Patients with HER2 Overexpressing Metastatic Breast Cancer:  A Randomized Phase III Study (TRAVIOTA), Protocol #01087.

2002

Sub-investigator – Daiichi Pharmaceutical Corp.:  A Randomized, Open-Label, Multicenter Phase III Study Comparing the Efficacy and Safety of a Combination of Intravenous DX-8951f (Exatecan Mesylate) Plus Gemcitabine to Gemcitabine Alone in Patients with Locally Advanced or Metastatic Cancer of the Exocrine Pancreas Who Have Not Received Prior Chemotherapy, Protocol #895A-PRT031.

2002

Sub-investigator – Novartis Pharmaceuticals Corp.:  A Prospective, Multicenter, Open-Label Clinical Evaluation of the Effect of I.V. Zometa 4mg on Pain, Quality of Life and Time in Infusion Chair in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients with Cancer-Related Bone Lesions, Protocol #CZOL446EUS16

2002

Sub-investigator – Amgen, Inc.: A Phase 2 Clinical Trial Testing AMG 412 in Combination with Rituxan (Rituximab) in Rituximab-naïve Subjects with Refractory or Recurrent Low-Grade, CD2-+ B-cell Non-Hodgkin’s Lymphoma, Protocol #20010138.

2002

Sub-investigator – Smith/Kline Beecham Pharmaceuticals: An Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin versus Etoposide/Cisplatin as Treatment for Chemotherapy-naïve Patients with Extensive Disease-Small Cell Lung Cancer, Protocol #SKF-104864A/389.

2002

Sub-investigator – Pharmacia & Upjohn, Inc: A Phase I/II Study of the Safety and Efficacy of PNU-166196A in Adult Patients with Multiple Myeloma that has Progressed on Prior Chemotherapy, Protocol #196-ONC-0100-006 2001.

2002

Sub-investigator – Immunex Corp.: An Open-Label, Single-Arm Trial of Patients with Metastatic Colorectal Cancer Receiving Irinotecan, 5-Fluorouracil, and Leucovorin Followed by LEUKINE ® (Sargramostim), A Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Protocol #001.002.1.

2002

Sub-investigator – ISIS Pharmaceuticals, Inc.: Phase 2 Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Combination with Docetaxel for Patients with Previously Treated Advanced Non-Small Cell Lung Cancer, Protocol #ISIS 2503-CS11.

2002

Sub-investigator – CancerVax Corporation:  A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy with BCG plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine versus BCG plus a Placebo as Post-Surgical Treatment for Stage III Melanoma, Protocol #CV-MMAIT-3-001.

2002

Sub-investigator – CancerVax Corporation:  A Phase III Randomized Double-Blind Trial of Immunotherapy with a Polyvalent Melanoma Vaccine, CancerVax™ plus BCG versus Placebo plus BCG as a Post-Surgical Treatment for Stage IV, Melanoma, Protocol #CV-MMAIT-4-001.

2002

Sub-investigator – Bayer, Inc.: A Single Agent BAY 56-3722 (formerly BAY 38-3441), Uncontrolled Phase II Study, in Patients with Recurrent or Metastatic Colorectal Cancer, Who are Considered Resistant/Refractory to Irinotecan, Protocol #100365.

2002

Sub-investigator – Pharmacia: Phase II Study of Brostacillin (PNU-166196A) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory or Resistant to Platinum-Based Chemotherapy, Protocol #196-ONC-0100-005.

2002

Sub-investigator - Genta, Incorporated/OCOG:  Randomized Phase III Study of Dexamethasone with or without Genasense™ (Bcl-2 Antisense Oligonucleotide) in Patients with Relapsed or Refractory Chronic Multiple Myeloma, Protocol #GMY302.

2002

Sub-investigator - Genta, Incorporated/OCOG:  Randomized Study of Fludarabine and Cyclophosphamide with or without Genasense™ (Bcl-2 Antisense Oligonucleotide) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia, Protocol #GL303.

2002

Sub-investigator – Titan Pharmaceuticals, Inc.: A Double-Blind, Randomized, Parallel-Group, Two-Arm, Placebo-Controlled, Multicenter Evaluation of CeaVac (3H1) Anti-idiotypic Antibody in the Management of Patients with Stage IV Colon or Rectal Carcinomas Receiving Fluorouracil (5-FU0 Plus Leucovorin (Folinic Acid [FA]), Protocol #TX3H1-108A.

2002

Sub-investigator – Titan Pharmaceuticals, Inc:  A Double-Blind, Randomized, Placebo-Controlled, Multicenter Evaluation of CeaVac (3H1) Anti-Idiotypic Monoclonal Antibody in the Management of Patients with Stage IV colon or Rectal Carcinomas Who Have Refused or are Unsuitable for Chemotherapy, Protocol #TX3H1-202B.

2002

2002

2002

Sub-investigator – Sarah Cannon Cancer Center/OCOG:  A Phase II Study of A Three-Day Schedule of Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian Carcinoma and Primary Peritoneal Carcinoma, Protocol #GYN-8, OCOG #2016.

2002

Sub-investigator – Loras Therapeutics, Inc./OCOG: A Phase III, Double-Blind, Multicenter, Randomized Study in Chemonaive Patients with Locally Advanced or Metastatic Pancreatic Cancer to Compare a Combination Therapy of Virulizin® plus Gemcitabine versus Placebo plus Gemcitabine; Optional Second-line Therapy may Include Continuation of Virulizin® or Placebo, Alone or in Combination with 5-Fluorouracil, Protocol #LOR/VIR/PO3/002, OCOG Protocol #2014.

2002

Sub-investigator – Sarah Cannon Cancer Center/OCOG:  Preoperative (Neodadjuvant) or Postoperative (Adjuvant) Therapy of Patients with Stage IB, II and IIIA Non-Small Cell Lung Cancer, Protocol #LUN53, OCOG Protoocol #2005.

2002

Sub-invesigator – Sarah Cannon Cancer Center/Minnie Pearl Cancer Research Network/OCOG:  A Randomized Phase III Comparison of Weekly Docetaxel versus Weekly Docetaxel/Gemcitabine in the Treatment of Elderly or Poor Performance Status Patients with Advanced Non-Small Cell Lung Cancer, Protocol #LUN 52, OCOG-2010.

2002

Sub-investigator – Sarah Cannon Cancer Center/Minnie Pearl Cancer Research Network/OCOG:  A Phase III Randomized Study of Paclitaxel, Carboplatin and Gemcitabine versus Gemcitabine and Vinorelbine as First Line Chemotherapy for Stage IIIB and IV Non-Small Cell Lung Cancer, Protocol #LUN54, OCOG #2011.

2002

Sub-investigator – Minnie Pearl Cancer Research Network/Sarah Cannon Cancer Center/OCOG:  Phase II Randomized Crossover Study of Doxorubicin HCl Liposome Injection (DOXIL®) versus Weekly Docetaxel (Taxotere®) in Patients in First Relapse Metastatic Breast Cancer, Protocol #BRE 43.

2002

Sub-investigator – Minnie Pearl Cancer Research Network/Sarah Cannon Cancer Center/OCOG: Phase II Trial of Weekly Docetaxel, Vinorelbine, and Herceptin in the First-Line Treatment of Patients with Metastatic Breast Cancer and Over expression of HER-2, Protocol #BRE 46.

2002

Sub-investigator – Sarah Cannon Cancer Center/OCOG:  Phase II Study of Weekly Docetaxel and Estramustine Monophosphate for Patients with Early Relapse or Hormone-Sensitive Metastatic Prostate Cancer, Protocol #GU11.

2002

Sub-investigator – OCOG: Phase II Study of Arsenic Trioxide (ATO) in Combination with Dexamethasone and Ascorbic Acid in Patients with Relapsed/Refractory Multiple Myeloma, protocol #OCOG 2013.

2002

Sub-investigator (2002)/Principal Investigator (2003) - Novartis Pharmaceuticals Corp.:  An Open-Label, Randomized, Multicenter Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER + and/or PR+ Breast Cancer Receiving Letrozole as Adjuvant Therapy, Protocol #CZOL446EUS32.

2002

Principal Investigator  - Titan Pharmaceuticals Inc:   An Open-label, Dose Escalation Study Combined Therapy with Pivanex and Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), Protocol #TTP-200-02-01

2002

Sub-investigator – Pharmatech:  A Phase II Study of Irinotecan HCI and Gemcitabine with or without Celecoxib in Stage IIIb/IV Advanced Non-Small Cell Lung Cancer (NSCLC), Protocol #POI-01-004-020.

2002

Sub-investigator – Favrille, Inc:  Phase II Trial of Rituxan ® plus FavId ™ (Tumor-Specific Idiotype-KLH) and GM-CSF Immunotherapy in Patients with Grade 1 or 2 Follicular B-Cell Lymphoma, Protocol #FavId-04.

2002

Sub-investigator – Sanofi-Synthelabo, Inc:   A Randomized, Prospective Study Comparing Three Regimens of Eloxatin ™ Plus Fluoropyrimidine For Evaluation of Safety and Tolerability in First Line Treatment of Patients with Advanced Colorectal Cancer (TREE STUDY), Protocol # ARD5099.